BioCentury
ARTICLE | Company News

Zealand brings in $205M for pipeline via royalty pharma deal

September 13, 2018 10:43 PM UTC

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million.

Sanofi (Euronext:SAN; NYSE:SNY), Zealand’s partner since 2003, markets Zealand’s lixisenatide in the U.S. as Adlyxin and in the EU as Lyxumia to treat Type II diabetes. Sanofi also markets a combination of lixisenatide plus its own Lantus insulin glargine in the U.S. as Soliqua 100/33 and in the EU as Suliqua...